Press Releases

AlloMap now in-network for over 80% of covered lives with all US payors BRISBANE, Calif. , May 03, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic

CareDx collaboration with Cibiltech provides prognostic information on allograft survival BRISBANE, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated,

OTTR acquisition will enable EMR integrations at transplant centers and longitudinal patient data management BRISBANE, Calif. , April 25, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically

BRISBANE, Calif. , April 23, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients, today announced that it will release financial results for the first quarter 2019 after the market

CareDx Files Second Lawsuit Against Natera BRISBANE, Calif. , April 10, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients, has filed a second lawsuit against Natera, Inc.

CareDx commitment to transplant innovation highlighted through seven podium and poster presentations BRISBANE, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically

CareDx protects innovation in transplantation by enforcing patent protection BRISBANE, Calif. , March 26, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated,

Cedars Sinai enrolls first patient in a study that uses AlloSure to characterize patient response to therapy BRISBANE, Calif. , March 13, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically

Alongside AlloSure Heart Validation, CareDx advances SHORE enrollment    BRISBANE, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value

AlloSure launch momentum drives 88% fourth quarter revenue growth BRISBANE, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic